Mass vaccination is a Phase 3 trial. This result is not surprising. Helsinki Declaration is clear. Immune related issues can take time to develop. The UK will very likely have seen these cases if vaccine linked. So we need to ask some questions....https://www.vg.no/nyheter/innenriks/i/wenlan/behandlende-lege-om-blodpropp-funn-ikke-sett-noe-i-denne-gaten-foer …
-
-
-
3. The Oxford vaccine made use of a previously experimental vaccine vector. Are the antibodies specific to the empty vector? This CAN be demonstrated using patient sera. This would be a GAME CHANGER. If these anti-platelet antibodies are specific to the Oxford vector, whoa!!!
Deze collectie tonen -
4. This is crucial. We need to know the source of these antibodies and we need to know their clinical significance. Immediately.
Deze collectie tonen
Einde van gesprek
Nieuw gesprek -
Het laden lijkt wat langer te duren.
Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.